Skip to content
Screener

Shattuck Labs, Inc. STTK Accretion (Amortization) of Discounts and Premiums, Investments

Accretion (Amortization) of Discounts and Premiums, Investments at other companies

Avalo Therapeutics logo
Avalo TherapeuticsAVTX
$418K+186%
Upstream Bio, Inc. logo
Upstream Bio, Inc.UPB
$39K-96.0%
Viridian Therapeutics, Inc. logo
Viridian Therapeutics, Inc.VRDN
$1.45M-6.5%
Spyre Therapeutics, Inc. logo
Spyre Therapeutics, Inc.SYRE
$2.06M-22.1%

Other financials

Income statement

See full
Revenue-
Operating income-$16.2M-24.0%
Net income-$15.2M-21.6%
EPS (diluted)-$0.12+50.0%

Balance sheet

See full
Cash & equivalents$63.3M+25.4%
Total debt$2.7M-10.0%
Total equity$211.1M+270%
Total assets$220.7M+243%

Cash flow

See full
Operating cash flow-$10.2M+2.4%
CapEx$78.0K
Free cash flow-$10.3M+1.6%

Valuation

See full
Market cap$694.34M+1,861%
Enterprise value$633.72M-5,344%
P/S694.3×+683×

Profitability

See full
Operating margin-5,578.7%-15,316pp
Net margin-5,256.8%-14,625pp
FCF margin-4,124%-23,818pp

Returns & leverage

See full
Return on equity-39.2%-12.5pp
Debt / equity0.0×
Current ratio27.6×+17.3×

Where this comes from

Reported directly by Shattuck Labs, Inc. in its filing.

Tagged under the XBRL concept us-gaap:AccretionAmortizationOfDiscountsAndPremiumsInvestments.

The source filing: Shattuck Labs, Inc.’s 10-Q, filed August 11, 2026.

Filed
Aug 11, 2026, 6:57 AM EDT
Fiscal quarter
Q2 FY2026
Calendar quarter
Q2 2026
Accession
0001628280-26-055483
Line itemSix Months Ended June 30, 2026Six Months Ended June 30, 2025
Stock-based compensation5,1483,611
Depreciation1,7421,865
Non-cash operating lease expense(417)241
Net accretion of investments(243)(1)
Changes in operating assets and liabilities:
Prepaid expenses and other current assets(561)2,020
Other assets(26)32
Accounts payable1,613(1,944)

Item 1. Condensed Financial Statements (Unaudited)

FAQ

What is Shattuck Labs, Inc.'s accretion (amortization) of discounts and premiums, investments?
Shattuck Labs, Inc. (STTK) reported accretion (amortization) of discounts and premiums, investments of $195K in Q2 2026.
What is the long-term trend for Shattuck Labs, Inc.'s accretion (amortization) of discounts and premiums, investments?
Over 3 years (2021 to 2025), Shattuck Labs, Inc.'s accretion (amortization) of discounts and premiums, investments has grown at a -46.9% compound annual growth rate (CAGR), from -$3.04M to $454K.
What does accretion (amortization) of discounts and premiums, investments mean?
This represents the periodic adjustment to the carrying value of investment securities to reflect the amortization of premiums or the accretion of discounts over the life of the instrument. It reconciles the difference between the purchase price and the face value of debt securities held by the company. This adjustment is essential for accurately reflecting the effective interest income earned on the investment portfolio.

Ask your AI about Shattuck Labs, Inc.'s accretion (amortization) of discounts and premiums, investments.

Connect your AI assistant and compare it to peers, right in your chat.

Connect your AI
Harbor at dusk
Claude